Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending October 20, 2019 Inspector General: NIH must improve conflict of interest reviews, SPARTAN: Apalutamide delays second progression in nonmetastatic CRPC, Risk of Contralateral Breast Cancer Highest for Women Under 40, MONARCH 2: Abemaciclib Plus Fulvestrant Improves Overall Survival, Ribociclib/Fulvestrant Boosts Survival in Advanced Breast Cancer, More must reads Must reads for theWeek ending October 13, 2019 Women Underrepresented as Oncology Trial Corresponding Authors, Professional Coaching Keeps Physicians in the Game, Treatment trends and prognostic findings illuminate male breast cancer journey, CMS Plans to Give MIPS an Overhaul, Hemophilia prevalence is nearly three times higher than previously reported, More must readsMust reads for theWeek ending October 6, 2019 CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma, Blood Group B May Indicate Shorter Survival in DLBCL, Study Confirms Poor Prognosis Post-HSCT in DLBCL, Abnormal MYC Status, p53 Expression Predict Survival in DLBCL, Rituximab Infusion Reactions Predicted By Patient, Disease Factors, More must readsMust reads for theWeek ending September 29, 2019 PAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancer, Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkers, Adjuvant radiotherapy no better than salvage post prostatectomy, Next-generation anti-BCMA CAR T shows promise for RRMM, German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance, More must readsMust reads for theWeek ending September 22, 2019 Closure of women’s health clinics may negatively impact cervical cancer outcomes, Business case for interoperability remains elusive, Oral triplet shows promise for relapsed/refractory myeloma, Combo could be new standard for transplant-eligible, newly diagnosed myeloma patients, Adding elotuzumab to lenalidomide/dexamethasone can prolong survival in relapsed/refractory myeloma, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 last »